InsidersTradesSigma
Biocryst Pharmaceuticals INC Stock: price and insider trades · United States · SEC (Form 4)
Track the Biocryst Pharmaceuticals INC share price and the full management transaction log of the company, a listed issuer based in United States. Shares trade on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Biocryst Pharmaceuticals INC has published 271 insider filings. Market capitalisation: €2.5bn. The latest transaction was reported on 15 June 2026 (Attribution). Among the most active insiders: Stonehouse Jon P. Every trade is accessible without an account.
271
Insider Decl.
0
Thresholds
€2m
27 ops.
Buy Volume
€2m
17 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Biocryst Pharmaceuticals INC Strong Buy (bullish), based on 10 analysts. Average price target: US$21.80.
30Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 872 of 25,535 companies
81.2
score / 100
Value78
Quality84
FCF yld12%
Earn yld9.4%
EV/EBITDA9.3x
ROE·
Gross mgn98%
Net mgn30%
Debt/EBITDA1.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 15 June 2026
Declarations271 total
15,294 sharesCommon StockSEC:0000882796-26-000035:0
15,294 sharesCommon StockSEC:0000882796-26-000037:0
15,294 sharesCommon StockSEC:0000882796-26-000039:0
15,294 sharesCommon StockSEC:0000882796-26-000041:0
15,294 sharesCommon StockSEC:0000882796-26-000043:0
15,294 sharesCommon StockSEC:0000882796-26-000045:0
15,294 sharesCommon StockSEC:0000882796-26-000052:0
15,294 sharesCommon StockSEC:0000882796-26-000053:0
15,294 sharesCommon StockSEC:0000882796-26-000055:0
1,262 shares@ US$8.910.0006% mcap50.0% of flowCommon StockSEC:0000882796-26-000025:0
1,122 shares@ US$8.910.0005% mcap2.7% of flowCommon StockSEC:0000882796-26-000027:0
631 shares@ US$8.910.0003% mcap8.0% of flowCommon StockSEC:0000882796-26-000029:0
631 shares@ US$8.910.0003% mcap0.2% of flowCommon StockSEC:0000882796-26-000031:0
1,262 shares@ US$8.910.0006% mcap100.0% of flowCommon StockSEC:0000882796-26-000033:0
62,500 shares@ US$9.540.031% mcap46.2% of flowCommon StockSEC:0000882796-26-000021:1
62,500 shares@ US$5.040.016% mcap48.8% of flowCommon StockSEC:0000882796-26-000021:0
62,500 shares@ US$5.040.016% mcap97.7% of flowCommon StockSEC:0000882796-26-000021
205,150 shares0Common StockSEC:0000882796-26-000019:0
49,933 shares@ US$6.300.016% mcap33.5% of flowCommon StockSEC:0000882796-26-000017:0
49,933 shares@ US$10.110.026% mcap53.7% of flowCommon StockSEC:0000882796-26-000017:1
2,582 sharesCommon StockSEC:0000882796-26-000003:0
12,272 shares0Common StockSEC:0000882796-26-000003:1
11,477 shares@ US$7.4110.4% of flowCommon StockSEC:0000882796-25-000041:0
14,142 shares@ US$3.225.6% of flowCommon StockSEC:0000882796-25-000041:1
10,091 shares@ US$5.046.2% of flowCommon StockSEC:0000882796-25-000041:2
25 of 271 declarations
About Biocryst Pharmaceuticals INC
BioCryst Pharmaceuticals, Inc. (ticker BCRX) is a U.S.-listed biotechnology company traded on NASDAQ in the United States, with a focused rare-disease strategy centered on hereditary angioedema (HAE) and selected adjacent programs. Founded in 1986 in Birmingham, Alabama, BioCryst later relocated its headquarters to Durham, North Carolina, where it is currently based. Over time, the company has evolved from a research-heavy biotech into a commercial-stage organization led by a core marketed product, while retaining a targeted pipeline of oral, small-molecule candidates. The company’s commercial engine is ORLADEYO (berotralstat), an oral, once-daily prophylactic therapy for HAE attacks. ORLADEYO is BioCryst’s key revenue driver and the main strategic asset around which the business is organized. Management continues to expand the product’s addressable market through label and formulation expansion efforts, including pediatric access initiatives. Beyond its lead franchise, BioCryst also advances earlier-stage programs, notably BCX17725 for Netherton syndrome, alongside other preclinical and early clinical assets. The portfolio has been streamlined over time, with some legacy programs discontinued or de-emphasized, reflecting a more disciplined capital allocation framework. From a competitive standpoint, BioCryst occupies a specialized but highly competitive HAE market, where patients and physicians can choose among multiple preventive or on-demand therapies. The company’s principal differentiator is convenience: an oral once-daily therapy can be attractive versus injectable alternatives, particularly in chronic prophylaxis. BioCryst also has an international footprint through commercial partnerships outside the United States, which extends ORLADEYO’s reach across multiple regions without requiring the company to build every market directly. Recent disclosures indicate solid commercial momentum, including strong 2025 ORLADEYO revenue growth and FDA acceptance of an NDA for ORLADEYO oral granules, a potential catalyst for pediatric expansion. BioCryst also announced the sale of its European ORLADEYO business, which suggests an ongoing portfolio optimization strategy and a sharper focus on the most value-accretive opportunities.
